38th week of 2009 patent applcation highlights part 30 |
Patent application number | Title | Published |
20090232733 | Diagnostic and Therapeutic Potential of Immune Globulin Intravenous (IGIV) Products - The present invention provides IGIV and IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The present invention also provides methods for obtaining IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The IGIV recognizes amyloid fibrils and partially denatured amyloidogenic precursor polypeptides. They are useful for treating diseases and conditions associated with amyloid deposition. The IGIV of the present invention also are useful for diagnosing and detecting amyloid deposition. | 2009-09-17 |
20090232734 | ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS - Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer. | 2009-09-17 |
20090232735 | USE OF FRUCTOSE-BASED THERAPIES FOR THE TREATMENT OF CANCER - The methods and compositions of the invention are based on the preferential utilization of fructose by cancer cells. This invention relates to compositions, methods and kits utilizing fructose and other monosaccharides for the treatment of cancer. This invention also relates to methods and kits for using compositions to mimic or corrupt metabolic pathways of fructose and/or signal transduction pathways related to cancer cells for the treatment of cancer. | 2009-09-17 |
20090232736 | Dual specificity antibodies and methods of making and using - Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-1β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental. | 2009-09-17 |
20090232737 | Purification of proteins - The present invention relates to a selectively soluble polymer capable of binding to a desired molecules in an unclarified mixture containing various biological materials and the methods of using such a polymer to purify a molecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and/or salt concentration and is rendered insoluble and precipitates out of solution upon a change in the process conditions. The polymer is capable of binding to the desired molecule (protein, polypeptide, etc) and remains capable of binding to that molecule even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered such as by elution and further processed. | 2009-09-17 |
20090232738 | Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity - The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-1 to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-1 protein or a molecule in a signal transduction pathway involving XBP-1. | 2009-09-17 |
20090232739 | Method of in Vivo Screening for cardiac Toxic Agents Using Teleost - This invention relates to a method of screening agents for cardiotoxicity based on the observations of the alteration of heart rate and heart rhythm, using teleost embryos and larvae. This invention also relates to a method for identification of gene(s) related to cardiac functions in teleost. | 2009-09-17 |
20090232740 | Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease - A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with said substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of said electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy. | 2009-09-17 |
20090232741 | Optical Imaging - This invention relates to a method for imaging of wet age-related macular degeneration (AMD) using a contrast agent comprising a vector attached to an optical imaging reporter, wherein the vector has affinity for receptors associated with angiogenesis. The invention further provides such methods for monitoring the effect of treatment of AMD. | 2009-09-17 |
20090232742 | METHOD FOR SCREENING AGENT WITH ANGIOGENIC-MODULATING ACTIVITIES USING TELEOST EMBRYO - This invention relates to a method of 3-tier system for screening compounds, herb extract or extract of herb combination in formula with angiogenic-modulating activities using transparent teleost embryos as model. | 2009-09-17 |
20090232743 | Foamable Microemulsion Compositions for Topical Administration - Described are ethanol-free foamable microemulsions for topical application, and method of making them. The propellants used in the compositions may be environmentally-friendly hydrofluoroalkanes. The foam compositions may also comprise one or more of a variety of active ingredients, including anti-inflammatory agents, anesthetics, and keratolytic agents. | 2009-09-17 |
20090232744 | Macrolide compositions having improved taste and stability - The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; or mixtures thereof and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability. | 2009-09-17 |
20090232745 | LICORICE LOLLIPOP THAT INHIBITS DENTAL CARIES FORMATION - This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject. | 2009-09-17 |
20090232746 | SILICONE POLYMER-SILICA SYSTEM - A chemical system comprising amodimethicone, dimethicone gum and silica is provided. The chemical system is useful in varying concentrations in antiperspirants of any form, including, but not limited to, solid stick, aerosol spray and liquid roll-on. Embodiments of the invention further include a method for preparing a chemical composition comprising amodimethicone, dimethicone gum and silica | 2009-09-17 |
20090232747 | THIOESTER COMPOUNDS AND THEIR USE IN FRAGRANCE OR FLAVOR APPLICATIONS - The present invention relates to thioester compounds and the incorporation and use of the new chemical entities as flavor and fragrance chemicals. | 2009-09-17 |
20090232748 | Virucidal activities of cetylpyridinium chloride - This disclosure relates to inventive methods for inactivating viral pathogens comprising providing a virucidal composition comprising a liquid media containing less than 1% weight per volume of a quaternary ammonium compound, such as cetylpyridinium chloride and between 0% and 0.5% weight per volume of citric acid, and contacting a surface targeted for disinfection with the virucidal composition. This disclosure further relates to inventive virucidal compositions comprising a liquid media, a quaternary ammonium compound, such as cetylpyridinium chloride, at a concentration of less than 1% weight per volume, citric acid at a concentration of between 0.0% and 0.5% weight per volume, an extender, and an enhancer. | 2009-09-17 |
20090232749 | Compositions for the acute and/or long term treatment of periodontal diseases - Composition comprising a mixture of | 2009-09-17 |
20090232750 | Compositions for indoor tanning - Compositions for inducing a natural tan of the skin is disclosed. The compositions contain D-ribose as the active ingredient plus a penetrant to deliver D-ribose to the basal cells and dermis of the skin. Compositions further containing emollients and emulsifiers are preferred. | 2009-09-17 |
20090232751 | High Sunscreen Efficiency Water-in-Oil Emulsion - The present invention relates to highly stable water-in-oil sunscreen emulsions that provide a high sunscreen efficiency (“SE”) having a sun protection factor (“SPF”) of X, where X is at least about 15, and having a sunscreen efficiency (“SE”) of at least 2, preferably at least 3, where SE is the ratio of SPF over the total weight percentage of sunscreen actives based on the total weight of the composition. The emulsions of the present invention provide photoprotection for the period corresponding to the labeled SPF throughout the period of exposure to natural sunlight and comprises (i) at least one sunscreen active and (ii) an alkyl dimethicone copolyol emulsifier in which the water-soluble, alkyl-soluble and silicone-soluble groups of the dimethicone copolyol are in specific ratios to each other. Preferably, the high SE water-in-oil emulsion comprises both a UV-A sunscreen and UV-B sunscreen. More preferably, the combination of sunscreen actives is photostable. | 2009-09-17 |
20090232752 | Silicone polyurethane blends - The invention describes the unexpected characteristics of blends, including crosslinked reaction products of elastomeric silicone polymers with various polyurethanes and their applications in personal care products. | 2009-09-17 |
20090232753 | Gel compositions - A gel, comprising: an ester and a polymer having at least one of the following rigid block groups; polystyrene, polyethylene, polyvinyl chloride, and phenolics as well as one elastic block that is a member of the group consisting of ethylene/butadiene copolymers, polyisoprene, polybutadiene, ethylene/propylene copolymers, or ethylene-propylene/diene copolymers, wherein the polymer is either triblock copolymers, star polymers, radial polymers, multi-block copolymers, or combinations thereof, wherein the composition is substantially free of mineral oils; wherein the ester's chemical formula is: | 2009-09-17 |
20090232754 | ENHANCED PHOTOSTABILITY OF SUNCARE COMPOSITIONS CONTAINING AVOBENZONE - The photostability of avobenzone in a sunscreen composition is stabilized against photodegradation using menthyl anthranilate. | 2009-09-17 |
20090232755 | COMBINATION THERAPIES FOR TREATING PHOTODAMAGED SKIN - Combination therapies for reducing the appearance of fine lines and wrinkles on aged skin or non-precancerous, normal photodamaged section of skin, in a patient not being treated for viral infection or skin cancer comprising (i) topical application of an imidazoquinoline amine derivative in a dermatologically-acceptable carrier in further combination with one or more cosmetic treatments selected from the group consisting of: (i) Light Emitting Diode (L.E.D.) Light Therapy; (ii) Intense Pulsed Light (I.P.L.) Therapy; (iii) laser skin resurfacing; (iv) mechanical exfoliation; (v) superficial, medium depth or deep chemical peels; (vi) radiofrequency treatment; (vii) ultrasound treatment; (viii) intradermal and intraepidermal injections with hyaluronic acid and derivatives thereof; and (ix) cryosurgery. | 2009-09-17 |
20090232756 | COSMETIC COMPOSITION COMPRISING AN ASCORBIC ACID OR SALICYLIC ACID COMPOUND - A composition in the form of an oil-in-water emulsion containing:
| 2009-09-17 |
20090232757 | Use of gamma-amino butyric acid as a depigmenting agent - Use of gamma aminobutyric acid, one of its salts or one of its lower alkyl ester or a polyol ester as depigmenting or melano modulating agent. | 2009-09-17 |
20090232758 | Brassocattleya marcella koss orchid extract and use thereof as skin depigmentation agent - This invention relates to an orchid extract of the | 2009-09-17 |
20090232759 | Hair Treatment Compositions - The invention provides a hair treatment composition comprising a combination of a sugar, an amine oxide and an amino acid. The composition is particularly suitable for the treatment of hair which is dry, damaged and/or prone to manageability problems. | 2009-09-17 |
20090232760 | Horse Bedding Product and Method - A layered bedding configuration installed in a stall for an animal for reducing odors. It comprises:
| 2009-09-17 |
20090232761 | Use of a Composition Comprising Pentane-1, 5-Diol as Deodorant - In one embodiment of the present invention, the use of a composition is disclosed including pentane-1,5-diol to reduce and/or eliminate odour from a mammal, such as odour from such as urine, faeces, liquids from leg ulcers, decubital ulcers, blood and perspiration. One embodiment of the present invention also relates to absorbent and/or sanitary products comprising pentane-1,5-diol. | 2009-09-17 |
20090232762 | COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS - The invention provides a polyamide compounds and compositions, in addition to methods for their preparation and methods for their use. The invention also provides micelle compositions that include encapsulated therapeutic agents, for example, nucleic acids or prodrugs, and methods for their preparation. The invention further provides methods of delivering therapeutic agents to cells and methods of activating therapeutic prodrugs. | 2009-09-17 |
20090232763 | AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING BORATE-POLYOL COMPLEXES - The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate, a preservative or both. | 2009-09-17 |
20090232764 | TRIBLOCK POLYMERS AND POLYMER COATINGS - The invention provides novel polymers, including triblock polymers, as well as methods of preparing the polymers, and compositions that include such polymers. The polymers can include at least three blocks, the first block that includes poly(styrene), the second block that includes a random arrangement of poly(ethylene) and poly(butylene), and a third block that includes functionalized poly(isoprene). Units of the functionalized poly(isoprene) block can include hydroxyl groups and one or more ether linked side chains comprising R | 2009-09-17 |
20090232765 | Method for improved refuge efficiency - A method to improve the efficiency of refuge crops in preventing the development of insects that are resistant to an insecticide. The method involves using an attractant to lure insects to the refuge and increase the population of survivors. The protected crops include cotton and corn. The refuge crop may be the same crop, a different crop, or a naturally occurring plant population. | 2009-09-17 |
20090232766 | Compositions for Inducing Immune Response Comprising Inverted Microsomes - A vaccine composition is provided which comprises inverted microsomes or fragments thereof from an animal cell in association with an externally disposed peptide antigen and a protein of the MHC. | 2009-09-17 |
20090232767 | METHODS AND COMPOSITIONS BASED ON DIPHTHERIA TOXIN-INTERLEUKIN-3 CONJUGATES - The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells. In other embodiments, the methods of the present invention relate to ex vivo purging of bone marrow or peripheral blood to remove cells that express one or more subunits of the interleukin-3 receptor such that the purged bone marrow or peripheral blood is suitable, e.g., for autologous stem cell transplantation to restore hematopoietic function. | 2009-09-17 |
20090232768 | NOVEL COMPOUNDS AND METHODS FOR THERAPY - Novel compounds having structure (1) | 2009-09-17 |
20090232769 | Pharmaceutical Composition For Treatment Of Blood Clotting Disorder - Disclosed is a pharmaceutical composition for the prevention or treatment of blood clotting disorder which can reduce a burden on a patient. The pharmaceutical composition comprises an effective amount of ribavirin or a derivative thereof or a pharmaceutically acceptable salt of ribavirin or the derivative. | 2009-09-17 |
20090232770 | PROCESS OF PRODUCTION OF BACTERIOPHAGE COMPOSITIONS AND METHODS IN PHAGE THERAPY FIELD - A method for producing bacteriophage stock compositions including (a) incubating a culture medium including at least one bacterial strain, at least one bacteriophage strain that can infect the bacterial strain, and at least one antibiotic, wherein the concentration of the antibiotic in the medium is in a range which causes about 0.1% to about 99.9% inhibition of the growth of the bacterial strain in the absence of the bacteriophage strain; (b) continuing incubation of the culture medium until bacterial lysis occurs, thereby obtaining a bacteriophage lysate; and preparing a crude bacteriophage extract from the culture medium. | 2009-09-17 |
20090232771 | Method of controlling cell functions - The present invention provides methods of screening genes associated with cell regeneration, growth and differentiation and regulators for cell regeneration, growth or differentiation; regulators for cell regeneration, growth or differentiation; and so on. More specifically, the present invention provides methods of screening genes associated with cell regeneration, growth and differentiation, which comprises the step of quantitatively analyzing expression levels of multiple genes collectively in a cell having a regeneration, differentiation or growth capability to thereby identify the genes associated with the regeneration, growth or differentiation of the cell; methods of screening genes associated with cell regeneration, growth and differentiation, which comprises the step of quantitatively analyzing expression levels of multiple genes collectively in a cell having a regeneration, differentiation or growth capability to thereby identify one or more genes that show higher expression levels in the cell or are specific in expression as compared to the other cells; and, the step of contacting at least one candidate substance capable of regulating the functions of the identified genes or their gene products with the cell and comparing changes before and after the contact; and so on. | 2009-09-17 |
20090232772 | HUMAN CORNEAL ENDOTHELIAL CELL-DERIVED PRECURSOR CELLS, CELLULAR AGGREGATES, METHODS FOR MANUFACTURING THE SAME, AND METHODS FOR TRANSPLANTING PRECURSOR CELLS AND CELLULAR AGGREGATES - Providing is cellular aggregates derived from corneal endothelial cells that, when transplanted, readily adhere to the parenchyma of cornea and function in a manner equivalent to corneal endothelial cells, and a method of transplantation of the cellular aggregates. Cellular aggregates derived from corneal endothelial cells. The cellular aggregates derived from corneal endothelial cells is prepared by culturing human corneal endothelial cells in a medium containing fetal bovine serum, growth factor and glucose; and then float culturing the cells obtained in a medium containing growth factor. A method of transplantation into the anterior chamber the cellular aggregate or the cellular aggregate prepared by the above method, comprising inserting a tube into the parenchyma of cornea, introducing the cellular aggregate into the anterior chamber through the inserted tube, and causing the cellular aggregate that has been introduced to adhere to Descemet's membrane by assuming in a downward-facing position. | 2009-09-17 |
20090232773 | Method for Distinguishing Mesenchymal Stem Cell Using Molecular Marker and Use Thereof - Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem cell and a connective tissue cell to distinguish the mesenchymal stem cell from the connective tissue cell. This method enables to distinguish an undifferentiated mesenchymal stem cell from other connective tissue cell such as fibroblasts, osteoblasts, chondrocytes and adipose cells with good accuracy. A mesenchymal stem cell given by this method or a composition comprising the mesenchymal stem sell can be used as a therapeutic for use in the regenerative medicine. | 2009-09-17 |
20090232774 | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance - The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject | 2009-09-17 |
20090232775 | Compounds and methods for increasing neurogenesis - The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis modulating agents. Novel methods for treating neurological disorders using neurogenesis modulating agents are disclosed. | 2009-09-17 |
20090232776 | USE OF IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION - Methods of treating, preventing or managing endothelial dysfunction and other disorders are disclosed. The methods encompass the administration of an immunomodulatory compound provided herein. Further described are methods of treatment using the immunomodulatory compounds in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed. | 2009-09-17 |
20090232777 | Expansion and Differentiation of Mesenchymal Stem Cells - A cell culture system for expanding and differentiating mammalian mesenchymal stem cells to chondrocytes is provided. Said cell culture system comprises a subpopulation of isolated MSC selected for their expression of integrin alpha 10, as well as additives promoting expansion and differentiation to chondrocytes. Methods and uses of said expanded and differentiated cells with a chondrogen phenotype are also provided, as well as compositions comprising said expanded and differentiated chondrocyte cells. | 2009-09-17 |
20090232778 | Methods and Compositions for Hair Growth - Methods and compositions for identifying and isolating dermal papilla cells are described. DP cells can be identified based on corin expression. Isolated DP cells can be used, e.g., to modulate hair growth. | 2009-09-17 |
20090232779 | OLIGODENDROCYTES DERIVED FROM HUMAN EMBRYONIC STEM CELLS FOR REMYELINATION AND TREATMENT OF SPINAL CORD INJURY - This invention provides populations of neural cells bearing markers of glial cells, such as oligodendrocytes and their precursors. The populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. Various combinations of differentiation factors and mitogens can be used to produce cell populations bearing markers of oligodendrocyte precursor cells. Upon further differentiation form complex processes characteristic of mature oligodendrocytes. The cells are capable of forming myelin sheaths, and can be used therapeutically improve function of the central nervous system. | 2009-09-17 |
20090232780 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION - This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation. | 2009-09-17 |
20090232781 | Treatment of liver diseases through transplantation of human umbilical mesenchymal stem cells - A method for treating liver diseases or liver damage, including but not limited to liver fibrosis, and/or aiding recovery from liver diseases, including but not limited to liver fibrosis, or liver damage in a subject, includes transplanting human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the area of liver disease or damage of the subject. | 2009-09-17 |
20090232782 | Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells - A method for treating or preventing an ischemic brain injury or neurological damage due to ischemia in a subject includes transplanting a therapeutically effective amount of human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the ischemic areas of the brain injury or the neurological damage of the subject. Recovery from neurological behavior deficits also is improved according by the method. | 2009-09-17 |
20090232783 | Method for Regulating Production of Hemoglobin Beta Chains - A method is described for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell utilizing a ferritin-H protein, a vector encoding ferritin-H, or an exogenous ferritin-H inducer. | 2009-09-17 |
20090232784 | ENDOTHELIAL PREDECESSOR CELL SEEDED WOUND HEALING SCAFFOLD - Compositions and processes for promoting wound healing are provided by the present invention which increase the rate and completeness of wound healing. Broadly described, an inventive composition includes a degradable scaffold of biocompatible material and a cell involved in wound healing, or a predecessor of such a cell, disposed in contact with the scaffold. In one embodiment, an albumin scaffold is provided with an endothelial cell predecessor disposed therein. Optionally, a cell involved in wound healing or a predecessor of such a cell is administered by local or systemic injection in conjunction with application of an inventive composition. Processes for promoting wound healing are provided as well as processes for producing the described compositions for promoting healing. | 2009-09-17 |
20090232785 | Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin - The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the prevention al and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least one polyunsaturated fatty acid and/or polyunsaturated fatty acid ester and/or a salt or derivative thereof in a physiologically-acceptable vehicle. | 2009-09-17 |
20090232786 | HERBAL COMPOSITION FOR CANCER TREATMENT - A therapeutic herbal composition comprising Saw Palmetto, Bromelain, Willow Herb, Grape Seed Complex, Wild Rosella, Liquorice, Passionfruit Seed and Selenium Yeast is claimed. The composition may be used as a general health promotant but is also useful as a treatment of cancer and inflammation. Prostate cancer and hyperplasia may be particularly beneficially addressed with the composition. The invention extends to a method of treatment using a composition as described. | 2009-09-17 |
20090232787 | CARCINOGEN DETOXIFICATION COMPOSITION AND METHOD - A pharmaceutical, food or cosmetic composition comprising a carrier and an effective amount of an active benzo(a)pyrene binding protein, whereby the protein is a SAM-dependent methyltransferase or a function-conservative variant or fragment thereof, having a SAM-binding domain specifically binding benzo(a)pyrene. | 2009-09-17 |
20090232788 | Enzyme With Microbial Lysis Activity From Trichoderma Reesei - The invention provides fungal polypeptides from | 2009-09-17 |
20090232789 | NOVEL PHARMACEUTICAL PREPARATION FOR PREECLAMPSIA, ECLAMPSIA, AND TOXEMIA, AND THEIR RELATED SYMPTOMS AND RELATED DISORDERS OF PREGNANCY - A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed. | 2009-09-17 |
20090232790 | Kit of Lyophilized Thrombin and Lyophilized Fibrinogen Used to Compound Fibrin Membrane, and Its Application - A kit of lyophilized thrombin and lyophilized fibrinogen comprises fibrinogen of 50-100 mg/ml, thrombin of 100-1000 IU/ml and 20-60 mmol/L CaCl | 2009-09-17 |
20090232791 | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers. | 2009-09-17 |
20090232792 | ANTIMICROBIAL CARBON - The present invention relates to antimicrobial carbon and to its use, especially for treating diseases and toxications of the gastrointestinal tracts, in particular diarrhoea. | 2009-09-17 |
20090232793 | Elastase inhibitor and acute leukemia - The invention relates to the use of an elastase inhibitor in the manufacture of a medicament for the treatment of leukemia, preferably acute leukemia and more preferably for the treatment of AML | 2009-09-17 |
20090232794 | Modulators of neuronal regeneration - The present invention provides methods and compositions related to CNS function and diseases. | 2009-09-17 |
20090232795 | 1B20 PCSK9 ANTAGONISTS - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2009-09-17 |
20090232796 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND - Provided herein relates to the field of cancer and its treatment by administering immunomodulatory compounds in combination with other compounds. In particular, a combination of an immunomodulatory compound and an anti-CD40 antibody and/or a CD40 ligand is provided. | 2009-09-17 |
20090232797 | PLASMODIUM MALARIAE AND PLASMODIUM OVALE GENES AND USES THEREOF - The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the | 2009-09-17 |
20090232798 | METHODS AND COMPOSITIONS FOR TREATING HERPES INFECTIONS - A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided. | 2009-09-17 |
20090232799 | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor - Anti-uPA antibodies and antigen-binding regions thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding regions, are described. Also described are methods of using such antibodies and antigen-binding regions to bind uPA epitopes and activate uPA function, such as inhibition of uPA mediated inflammation. Epitopes that can be used to activate uPA function and anti-inflammation activity are also described, as well as methods of identifying compounds that can bind them. | 2009-09-17 |
20090232800 | E1-MINUS ADENOVIRUSES AND USE THEREOF - The present invention is related to a virus, preferably an adenovirus, characterised in that the virus comprises:
| 2009-09-17 |
20090232801 | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof - The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions. | 2009-09-17 |
20090232802 | Compositions and methods for the treatment of natural killer cell related diseases - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2009-09-17 |
20090232803 | ANTIBODIES TO HUMAN IL-1BETA - An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides. | 2009-09-17 |
20090232804 | HUMANIZED ANTIBODIES SPECIFIC FOR VON WILLEBRAND FACTOR - The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders. | 2009-09-17 |
20090232805 | METHODS OF INHIBITING RECEPTOR TYROSINE KINASES WITH AN EXTRACELLULAR ANTAGONIST AND AN INTRACELLULAR ANTAGONIST - The present invention relates to methods of inhibiting receptor tyrosine kinases by utilizing a combination of both an extracellular and an intracellular RTK antagonist. The extracellular RTK antagonist is a biological molecule or a small molecule that inhibits activation of the receptor tyrosine kinase by interacting with the extracellular binding region of the receptor. The intracellular RTK antagonist is a biological molecule or small molecule that inhibits tyrosine kinase activity of the receptor tyrosine kinase by interacting with the receptor's intracellular region bearing a kinase domain or by interacting with an intracellular protein involved in the signaling pathway of the receptor tyrosine kinase. The present invention also provides methods of treating tyrosine kinase dependent diseases, and compositions for use in such methods thereof, by administering a combination of both an extracellular and an intracellular RTK antagonist. | 2009-09-17 |
20090232806 | Anti-CD70 Antibody And Its Use For The Treatment And Prevention Of Cancer And Immune Disorders - Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject. | 2009-09-17 |
20090232807 | GLP-1 ANALOG FUSION PROTEIN FORMULATIONS - The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1 -Fc fusions at a pH outside the described ranges. The formulations comprising a GLP- | 2009-09-17 |
20090232808 | MOLECULES AND CHIMERIC MOLECULES THEREOF - The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the tumour necrosis factor (TNF) superfamily such as TNF-a, Lymphotoxin-a (LT-a), TNFRI, TNFRII, OX40, BAFF, NGFR, Fas Ligand or chimeric molecules thereof comprising at least a portion of the protein molecule, such as TNF-a-Fc, LT-a-Fc, TNFRI-Fc, TNFRII-Fc, OX40-Fc, BAFF-Fc, NGFR-Fc, Fas Ligand-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications. | 2009-09-17 |
20090232809 | Type 2 cytokine receptor and nucleic acids encoding same - The present invention provides novel isolated CRF2-13 polynucleotides and polypeptides encoded by the CRF2-13 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-13 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-13 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-13 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses. | 2009-09-17 |
20090232810 | IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF - Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker. | 2009-09-17 |
20090232811 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 2009-09-17 |
20090232812 | MUC1 EXTRACELLULAR DOMAIN AND CANCER TREATMENT COMPOSITIONS AND METHODS DERIVED THEREFROM - The present invention provides compositions and methods for inhibiting the proliferation of cancer cells and for the treatment of tumors with antagonists of the binding of ligands to the extracellular domain of MUC1, such binding being related to an oncogenic function of MUC1. | 2009-09-17 |
20090232813 | Four-Jointed Box (FJX1) In Cancer Diagnosis and Treatment - The present invention relates to a new tumor suppressor, designated FJX1. Also described are diagnostic, prognostic and therapeutic uses of the FJX1 protein and the FJX1 gene, alone or in combination with traditional cancer therapies. | 2009-09-17 |
20090232814 | Cancer biomarker genes and gene products and methods for using the same - Using gene expression analysis, specific biomarker genes and gene products have been identified which are activated in transformed cells, but suppressed in nontransformed cells; or suppressed in transformed cells, but activated in transformed cells affected by Contact Normalization. Thus, the present invention features compositions and methods for detecting, diagnosing, treating and prognosing cancer. | 2009-09-17 |
20090232815 | ANTIBODIES THAT BIND TO PLEIOTROPHIN GROWTH FACTOR RECEPTOR - This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders. | 2009-09-17 |
20090232816 | IL-1 ETA DNA AND POLYPEPTIDES - The invention is directed to novel purified and isolated IL-1 eta polypeptides and fragment thereof, the polynucleotides encoding such, polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof. | 2009-09-17 |
20090232817 | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 2009-09-17 |
20090232818 | Prognosis and Treatment of Breast Cancer - The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis in breast cancer cells by inhibiting the expression or activity of Spot 14. Compositions and methods for treating breast cancer are also provided. | 2009-09-17 |
20090232819 | METHOD USING SNAIL TRANSCRIPTIONAL REPRESSOR - Provided is a prognostic molecular marker for breast cancer recurrence. Expression of Snail, a zinc finger transcriptional repressor gene, is correlated to the risk of breast cancer recurrence, and to the likelihood of recurrence-free survival in subjects diagnosed with breast cancer. Further provided are methods of identifying therapeutic compositions for treating breast cancer to reduce recurrence associated with high expression of Snail, and methods of controlling Snail expression for research and therapeutic purposes. | 2009-09-17 |
20090232820 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 2009-09-17 |
20090232821 | Use Of A Growth-Stimulating Protein - This invention relates to the inhibition of a newly discovered growth-stimulating protein in an individual. Further, the invention relates to a method for preventing or treating a cancer, or preventing or treating cancer growth, invasion or metastasis, or preventing or treating other hyperproliferative diseases in an individual, by down regulating the expression of said growth-stimulating protein or by inactivating said protein. Still further, the invention concerns a method for diagnosing cancer or other hyperproliferative diseases in an individual based on said growth-stimulating protein. | 2009-09-17 |
20090232822 | LUNG DISEASE TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung diseases (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung. | 2009-09-17 |
20090232823 | ANTI-TYRP1 ANTIBODIES - The present invention provides for fully human antibodies and chimeric antibodies that bind human TYRP1 antigen with an affinity comparable to or higher than TA99, a murine antibody specific to TYRP1. The invention further provides polynucleic acids and host cells that encode and express these antibodies. The invention also provides for methods of modulating activity of TYRP1, treating growth of a cancer cell, and treating a malignant melanoma in mammals by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment. | 2009-09-17 |
20090232824 | BIVM (BASIC, IMMUNOGLOBULIN-LIKE VARIABLE MOTIF-CONTAINING) GENE, TRANSCRIPTIONAL PRODUCTS, AND USES THEREOF - The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs: 1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected of containing BIVM genes, BIVM transcriptional products, or BIVM translational products. These methods are also useful for the detection of BIVM orthologs. Other embodiments provide polypeptide and/or nucleic acid vaccines for the induction of an immune response to in an individual. Kits for detecting the presence of BIVM genes, orthologs thereof, BIVM polypeptides, or BIVM transcriptional products are also provided. | 2009-09-17 |
20090232825 | Methods and Compositions For Modulating Immunity - Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer. | 2009-09-17 |
20090232826 | Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2 - The invention relates to a monoclonal antibody or a fragment thereof comprising in the H chain variable region at least one complementarity determining region (CDR) selected among CDR1, CDR2 and CDR3 having, respectively, an amino acids sequence set forth as SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or functional analogues thereof. | 2009-09-17 |
20090232827 | Compositions and methods of use of compounds to increase cancer patient survival time - The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients. | 2009-09-17 |
20090232828 | Methods of Using IGFIR and ABL Kinase Modulators - The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s). | 2009-09-17 |
20090232829 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS - The present invention is directed to methods of treating an inflammatory condition in a patient. This method includes providing a therapeutic agent that is a vascular endothelial growth factor receptor-3 (VEGFR-3) agonist or a nucleic acid molecule encoding a VEGFR-3 agonist. The present invention is further directed to pharmaceutical compositions and therapeutic systems for treating an inflammatory condition. | 2009-09-17 |
20090232830 | Modified HIV-1 Envelope Proteins - The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these epitopes. | 2009-09-17 |
20090232831 | METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION - A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC | 2009-09-17 |
20090232832 | Polyclonal antiserum against a universal tumor antigen - The present invention relates to a polyclonal antiserum against a universal tumor antigen obtainable by (i) eliciting an in vivo humoral response against embryonic tissue in a non-human vertebrate, whereby said embryonic tissue is of the same genetic line as the non-human vertebrate; (ii) recovering from the immunized non-human animal spleen and isolating from said spleen individual spleen cells/lymphocytes; (iii) eliciting a second in vivo humoral response to the isolated spleen cells/lymphocytes suspension obtained in step (ii) in a further non-human animal of the same genetic line as the non-human animal of step (i); and (iv) isolating the desired polyclonal antiserum from said animal. Furthermore, the invention provides for the use of the polyclonal antiserum for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of cancer, in particular cancer of the breast, lung, prostate, uterus, colon, stomach or bladder. Additionally the invention relates to the use of the polyclonal serum of the invention for the preparation of a pharmaceutical composition, wherein said pharmaceutical composition is to be administered to a subject in need of treatment in combination with a further anti-proliferative drug or medicament. | 2009-09-17 |